Axsome Therapeutics, Inc. (NASDAQ:AXSM) is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.57 per share.
Looking ahead, the full year loss are expected at $ 2.65 per share.
Stock Performance
Shares of Axsome Therapeutics, Inc. traded up $ 5.29 or 7.62 percent on Wednesday, reaching $ 74.73 with volume of 343.40 thousand shares. Axsome Therapeutics, Inc. has traded high as $ 75.30 and has cracked $ 69.44 on the downward trend
The closing price of $ 74.73, representing a 239.06 % increase from the 52 week low of $ 20.48 and a 36.84 % decrease over the 52 week high of $ 109.94.
The company has a market capital of $ 2.79 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 29th September 2020, initiated by Bank of America at Underperform rating, with $ 66.00 target price.
- On 10th September 2020, initiated by Morgan Stanley at Overweight rating, with $ 102.00 target price.
Conference Call
Axsome Therapeutics, Inc. will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.axsome.com
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimers disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes.
